Last reviewed · How we verify
Marketed varicella vaccine_Lot 2
Marketed varicella vaccine_Lot 2 is a Live attenuated vaccine Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Prevention of varicella (chickenpox) in children and adults, Prevention of herpes zoster (shingles) in immunocompetent individuals.
This live attenuated varicella-zoster virus vaccine stimulates the immune system to produce antibodies and cell-mediated immunity against varicella (chickenpox).
This live attenuated varicella-zoster virus vaccine stimulates the immune system to produce antibodies and cell-mediated immunity against varicella (chickenpox). Used for Prevention of varicella (chickenpox) in children and adults, Prevention of herpes zoster (shingles) in immunocompetent individuals.
At a glance
| Generic name | Marketed varicella vaccine_Lot 2 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Live attenuated vaccine |
| Target | Varicella-zoster virus (VZV) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains a weakened form of the varicella-zoster virus (VZV) that replicates in the body at low levels, triggering both humoral and cellular immune responses without causing clinical disease. This primes the immune system to recognize and rapidly respond to wild-type VZV infection, preventing or significantly reducing the severity of chickenpox and reducing the risk of herpes zoster (shingles) later in life.
Approved indications
- Prevention of varicella (chickenpox) in children and adults
- Prevention of herpes zoster (shingles) in immunocompetent individuals
Common side effects
- Injection site reactions (erythema, swelling, pain)
- Fever
- Rash (vaccine strain)
- Myalgia
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Marketed varicella vaccine_Lot 2 CI brief — competitive landscape report
- Marketed varicella vaccine_Lot 2 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Marketed varicella vaccine_Lot 2
What is Marketed varicella vaccine_Lot 2?
How does Marketed varicella vaccine_Lot 2 work?
What is Marketed varicella vaccine_Lot 2 used for?
Who makes Marketed varicella vaccine_Lot 2?
What drug class is Marketed varicella vaccine_Lot 2 in?
What development phase is Marketed varicella vaccine_Lot 2 in?
What are the side effects of Marketed varicella vaccine_Lot 2?
What does Marketed varicella vaccine_Lot 2 target?
Related
- Drug class: All Live attenuated vaccine drugs
- Target: All drugs targeting Varicella-zoster virus (VZV)
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Prevention of varicella (chickenpox) in children and adults
- Indication: Drugs for Prevention of herpes zoster (shingles) in immunocompetent individuals
- Compare: Marketed varicella vaccine_Lot 2 vs similar drugs
- Pricing: Marketed varicella vaccine_Lot 2 cost, discount & access